Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev2008; 29: 726-776.
2.
Verstuyf A., Carmeliet G., Bouillon R. and Mathieu C.Vitamin D: a pleiotropic hormone. Kidney Int2010; 78: 140-145.
3.
Drechsler C. , Pilz S., Obermayer-Pietsch B., Verduijn M., Tomaschitz A., Krane V., et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J2010; 31: 2253-2261.
4.
Meems LM, van der Harst P., van Gilst WH and de Boer RAVitamin D biology in heart failure: molecular mechanisms and systematic review . Curr Drug Targets2011; 12: 29-41.
5.
Liu LC, Voors AA, van Veldhuisen DJ, van der Veer E., Belonje AM, Szymanski MK, et al. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail2011; DOI: 10.1093/eurjhf/hfr032.
6.
Melamed ML, Michos ED, Post W. and Astor B.25-hydroxyvitamin D levels and the risk of mortality in the general population . Arch Intern Med2008; 168: 1629-1637.
7.
Müller DN , Kleinewietfeld M. and Kvakan H.Vitamin D review. JRAAS2011.
8.
Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus JM and Thadhani R.Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med2003; 349: 446-456.
9.
Autier P. and Gandini S.Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med2007; 167: 1730-1737.
10.
The VITAL Study, www.vitalstudy.org
11.
Brewer LC, Michos ED and Reis JPVitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets2011; 12: 54-60.
12.
Dusso AS, Thadhani R. and Slatopolsky E.Vitamin D receptor and analogs. Semin Nephrol2004; 24: 10-16.
13.
Brancaccio D., Bommer J. and Coyne D.Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. Drugs2007; 67: 1981-1998.
